Topline Data from Three Phase 3 Studies Evaluating DT120 Orally Disintegrating Tablet (ODT) for GAD and MDD Expected in 2026: Voyage in 2Q, Panorama in 2H, and Emerge Mid-Year Company Presenting at ...
Ian Mortimer, President and CEO, emphasized the nearing completion of patient recruitment for the X-TOLE2 Phase 3 epilepsy study and stated, "delivering data from our X-TOLE2 study remains our number ...
Definium Therapeutics, Inc. (formerly Mind Medicine (MindMed) Inc.) (the "Company" or “Definium") unveiled its new brand today, marking a decisive step forward as the company leads psychiatry toward a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results